BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 29028349)

  • 1. Proteomic Profiling of β-hCG-Induced Spheres in BRCA1 Defective Triple Negative Breast Cancer Cells.
    Sengodan SK; Rajan A; Hemalatha SK; Nadhan R; Jaleel A; Srinivas P
    J Proteome Res; 2018 Jan; 17(1):276-289. PubMed ID: 29028349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 regulation on β-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
    Sengodan SK; Nadhan R; Nair RS; Hemalatha SK; Somasundaram V; Sushama RR; Rajan A; Latha NR; Varghese GR; Thankappan RK; Kumar JM; Chil A; Anilkumar TV; Srinivas P
    Oncogenesis; 2017 Sep; 6(9):e376. PubMed ID: 28869585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-hCG-induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.
    Sengodan SK; Hemalatha SK; Nadhan R; Somanathan T; Mathew AP; Chil A; Kopczynski J; Nair RS; Kumar JM; Srinivas P
    Carcinogenesis; 2019 Nov; 40(11):1415-1426. PubMed ID: 30963174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells.
    Crippa E; Folini M; Pennati M; Zaffaroni N; Pierotti MA; Gariboldi M
    Oncotarget; 2016 Apr; 7(14):18594-604. PubMed ID: 26919240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.
    Martinez-Outschoorn UE; Balliet R; Lin Z; Whitaker-Menezes D; Birbe RC; Bombonati A; Pavlides S; Lamb R; Sneddon S; Howell A; Sotgia F; Lisanti MP
    Cell Cycle; 2012 Dec; 11(23):4402-13. PubMed ID: 23172369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 promoter hypermethylation in human placenta: a hidden link with β-hCG expression.
    Nadhan R; Vaman JV; Sengodan SK; Hemalatha SK; Chellappan N; Sadasivan S; Pasuthottiyil Varkey A; Yesodharan S; Raji Sathyanpillai K; Bhuvaneswari Venugopal AK; Prameelakumari Sreenivasan S; Rajan A; Latha NR; Varghese GR; Thankappan R; Achyutuni S; Sreekumar Usha JD; Vijayamma Anilkumar T; Srinivas P
    Carcinogenesis; 2020 Jul; 41(5):611-624. PubMed ID: 31219560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
    Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A
    BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
    Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
    BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-catenin.
    Li H; Sekine M; Tung N; Avraham HK
    Mol Cancer Res; 2010 Mar; 8(3):407-20. PubMed ID: 20215423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo.
    Tassone P; Di Martino MT; Ventura M; Pietragalla A; Cucinotto I; Calimeri T; Bulotta A; Neri P; Caraglia M; Tagliaferri P
    Cancer Biol Ther; 2009 Apr; 8(7):648-53. PubMed ID: 19333003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
    Tassone P; Blotta S; Palmieri C; Masciari S; Quaresima B; Montagna M; D'Andrea E; Eramo OP; Migale L; Costanzo F; Tagliaferri P; Venuta S
    Int J Oncol; 2005 May; 26(5):1257-63. PubMed ID: 15809716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
    Heublein S; Mayr D; Meindl A; Kircher A; Jeschke U; Ditsch N
    J Exp Clin Cancer Res; 2017 Apr; 36(1):57. PubMed ID: 28427429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human chorionic gonadotropin induces signaling pathways towards cancer prevention in the breast of BRCA1/2 mutation carriers.
    Su Y; Dang NM; Depypere H; Santucci-Pereira J; Gutiérrez-Díez PJ; Kanefsky J; Janssens JP; Russo J
    Eur J Cancer Prev; 2023 Mar; 32(2):126-138. PubMed ID: 35881946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.
    Tassone P; Tagliaferri P; Perricelli A; Blotta S; Quaresima B; Martelli ML; Goel A; Barbieri V; Costanzo F; Boland CR; Venuta S
    Br J Cancer; 2003 Apr; 88(8):1285-91. PubMed ID: 12698198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
    Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
    Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
    Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.
    Buckley NE; Haddock P; De Matos Simoes R; Parkes E; Irwin G; Emmert-Streib F; McQuaid S; Kennedy R; Mullan P
    Oncotarget; 2016 Apr; 7(15):19884-96. PubMed ID: 26943587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function.
    Kumaraswamy E; Wendt KL; Augustine LA; Stecklein SR; Sibala EC; Li D; Gunewardena S; Jensen RA
    Oncogene; 2015 Aug; 34(33):4333-46. PubMed ID: 25417703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB).
    Nair RS; Kumar JM; Jose J; Somasundaram V; Hemalatha SK; Sengodan SK; Nadhan R; Anilkumar TV; Srinivas P
    Sci Rep; 2016 May; 6():26631. PubMed ID: 27220670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.